Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome

SciSparc secures FDA approval for Phase IIb clinical trial of SCI-110, targeting unmet needs in Tourette Syndrome, Global trial begins soon. read more

Read Full Article